Repurposing of erythropoietin as a neuroprotective agent against methotrexate-induced neurotoxicity in rats
Journal of Psychopharmacology · 2025-02 · 39 (2) · 147-163
DOI: 10.1177/02698811241295379 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Psychopharmacology, online erschienen am 13.11.2024. Verfasst von Nadine C Sabry und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Pharmacology and Toxicology, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Erythropoietin, Neuroprotective Agents, Methotrexate, Neurotoxicity Syndromes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 110 Literaturangaben.
Abstract (Originalsprache)
Background
Methotrexate (MTX) is a cytotoxic drug that can trigger neurotoxicity via enhancing oxidative stress, apoptosis, and inflammation. On the other hand, erythropoietin (EPO) functions as an antioxidant, anti-apoptotic, and anti-inflammatory agent, in addition to its hematopoietic effects.
Aim
The present study was developed to examine the neuroprotective impact of EPO against MTX-provoked neurotoxicity in rats.
Methods
Chemo fog was elicited in Wistar rats via injection of one dosage of MTX (20 mg/kg, i.p) on the sixth day of the study. EPO was injected at 500 IU/kg/day, i.p for 10 successive days.
Results
MTX triggered memory and learning impairment as evidenced by Morris water maze, passive avoidance, and Y-maze cognitive tests. In addition, MTX induced oxidative stress as evident from the decline in hippocampal Nrf2 and HO-1 levels. MTX brought about apoptosis, as demonstrated by the elevation in p53, caspase-3, and Bax levels, as well as the decrease in Bcl2 levels. MTX also decreased Beclin-1, an autophagy-related marker, and increased P62 expression. In addition, MTX downregulated Sirt-1/AKT/FoxO3a pathway and increased miRNA-34a gene expression. Moreover, MTX increased acetylcholinesterase activity and reduced neurogenesis. EPO administration remarkably counteracted MTX-induced molecular and behavioral disorders in rat hippocampi.
Conclusion
Our findings impart preclinical indication for repurposing of EPO as a promising neuroprotective agent through modulating miRNA-34a, autophagy, and the Sirt-1/FoxO3a signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Department of Pharmacology and Toxicology, Ain Shams University, Cairo, Egypt.
ORCID-Profile: Haidy E Michel
Zitieren
APA
Sabry, N. C., Michel, H. E., & Menze, E. T. (2025). Repurposing of erythropoietin as a neuroprotective agent against methotrexate-induced neurotoxicity in rats. Journal of Psychopharmacology, 39(2), 147-163. https://doi.org/10.1177/02698811241295379
Vancouver
Sabry NC, Michel HE, Menze ET. Repurposing of erythropoietin as a neuroprotective agent against methotrexate-induced neurotoxicity in rats. Journal of Psychopharmacology. 2025;39(2):147-163. doi:10.1177/02698811241295379
BibTeX
@article{Sabry2025,
author = {Sabry, Nadine C and Michel, Haidy E and Menze, Esther T},
title = {Repurposing of erythropoietin as a neuroprotective agent against methotrexate-induced neurotoxicity in rats},
journal = {Journal of Psychopharmacology},
year = {2025},
volume = {39},
number = {2},
pages = {147--163},
doi = {10.1177/02698811241295379}
}
EUVIMED